## UNITED STATES SECURITIES AND EXCHANGE COMMISSION JANUARY 4, 2012

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## **Galectin Therapeutics, Inc.**

## File No. 001-31791 - CF# 27613

Galectin Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 10, 2011.

Based on representations by Galectin Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.2 through October 18, 2018

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jennifer Riegel Special Counsel